None listed
Conditions
Brief summary
This pilot (preliminary) study aims to determine if taking supplements of CoEnzymeQ10 (a vitamin with antioxidant properties) improves the relaxation function of artery blood vessels in people with type 2 diabetes.
Interventions
An open-label non-randomised sequential pilot trial. Whilst continuing on their usual medications (which may include lipid-lowering and/or antihypertensive therapies), eligible subjects are supplemented with oral CoEnzymeQ10 (CoQ) 200mg daily for four weeks (supplementation period 1). Following this, CoQ supplementation is ceased for four weeks (washout period - no placebo given), before being restarted at the same dose for a further four weeks (supplementation period 2).
Sponsors
Professor Gerald F Watts
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Adult subjects with type 2 diabetes with screening FMD of <5%, who were able to provide informed consent.
Exclusion criteria
Uncontrolled glycaemia (HbA1c 9.0% or greater); daytime insulin use; advanced renal impairment (serum creatinine>300umol/L); clinical cardiac failure; recent vascular event (acute myocardial infarction or stroke within preceding three months).
Outcome results
None listed